-
公开(公告)号:US11819518B2
公开(公告)日:2023-11-21
申请号:US17245133
申请日:2021-04-30
IPC分类号: A61K38/00 , A61K35/17 , C07K14/47 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/725 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/574
CPC分类号: A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4727 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/57484 , A61K2039/5158 , C12N2310/16 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N2333/70539 , G01N2500/04
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US10906938B2
公开(公告)日:2021-02-02
申请号:US16903119
申请日:2020-06-16
发明人: Hans-Georg Rammensee , Juliane Walz , Daniel Johannes Kowalewski , Stefan Stevanovic , Simon Walz
IPC分类号: C07K7/06 , C07K14/705 , A61K38/00 , C12N5/0783 , A61K35/17 , A61K39/00 , C07K16/00 , C07K16/30 , C07K7/08 , A61P35/00 , G01N33/574 , G01N33/53
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US10899820B2
公开(公告)日:2021-01-26
申请号:US16911109
申请日:2020-06-24
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
4.
公开(公告)号:US10364271B2
公开(公告)日:2019-07-30
申请号:US16179677
申请日:2018-11-02
IPC分类号: A61K38/00 , C07K7/06 , C12N5/0783 , C12Q1/6886 , G01N33/574 , G16B35/00 , G16C20/60 , C07K14/74 , C07K14/47 , A61K39/00
摘要: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
5.
公开(公告)号:US20180311330A1
公开(公告)日:2018-11-01
申请号:US16032231
申请日:2018-07-11
发明人: Hans-Georg Rammensee , Stefan Stevanovic , Juliane Stickel , Daniel Johannes Kowalewski , Claudia Berlin
IPC分类号: A61K39/00 , C07K14/47 , C12Q1/6886 , G01N33/50 , A61K35/17 , C07K14/725 , C07K7/02 , C07K7/08 , C07K7/06 , C12N9/90
CPC分类号: A61K39/0011 , A61K35/17 , A61K2039/5156 , A61K2039/5158 , A61K2039/572 , C07K7/02 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K2319/70 , C12N5/0638 , C12N9/14 , C12N9/90 , C12Q1/6886 , C12Q2600/136 , C12Y306/04004 , C12Y599/01002 , G01N33/505
摘要: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号:US11345737B1
公开(公告)日:2022-05-31
申请号:US17465460
申请日:2021-09-02
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11214608B2
公开(公告)日:2022-01-04
申请号:US17350964
申请日:2021-06-17
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11103534B2
公开(公告)日:2021-08-31
申请号:US16916220
申请日:2020-06-30
发明人: Juliane Sarah Walz , Daniel Johannes Kowalewski , Markus Loeffler , Moreno Di Marco , Nico Trautwein , Annika Nelde , Stefan Stevanovic , Hans-Georg Rammensee , Sebastian Haen
IPC分类号: A61K35/17 , A61P35/00 , C07K7/06 , C07K14/74 , C07K16/28 , C07K14/725 , C12N15/115 , A61K39/00 , C12N5/0783 , C07K14/47 , G01N33/50
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
9.
公开(公告)号:US10993963B2
公开(公告)日:2021-05-04
申请号:US16793721
申请日:2020-02-18
发明人: Juliane Sarah Walz , Daniel Johannes Kowalewski , Markus Loeffler , Moreno Di Marco , Nico Trautwein , Annika Nelde , Stefan Stevanovic , Hans-Georg Rammensee , Sebastian Haen
IPC分类号: A61K35/17 , A61P35/02 , A61P35/00 , C12N5/0783 , C07K14/74 , C07K16/28 , C07K14/725 , C12N15/115 , A61K39/00 , C07K14/47 , A61K38/00
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
10.
公开(公告)号:US10899794B2
公开(公告)日:2021-01-26
申请号:US16903077
申请日:2020-06-16
发明人: Hans-Georg Rammensee , Juliane Walz , Daniel Johannes Kowalewski , Stefan Stevanovic , Simon Walz
IPC分类号: C07K7/06 , C07K14/705 , A61K38/00 , C12N5/0783 , A61K35/17 , A61K39/00 , C07K16/00 , C07K16/30 , C07K7/08 , A61P35/00 , G01N33/574 , G01N33/53
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-